Week of April 25, 2022

This week we highlight a bold move to continue clinical trial progress, how the contract research organization industry perceives the state of biotech funding, and machine learning and the fight against long COVID-19. We also weigh COVID-19 risks and a White House event, and the Food and Drug Administration’s first approval of a treatment for young children. Each week we highlight five things you need to know about in the life sciences industry. Here’s the latest.

In a move we haven’t seen yet and an effort to maintain clinical trial progress for its multiple sclerosis patients in Ukraine, Sanofi has moved its MS patients out of Ukraine and into areas west of the country. About 11% of Sanofi’s MS study sites are in Ukraine.

First-quarter earnings calls are still taking place. With some nervousness surrounding biotech funding as a result of this year’s market slowdown, we thought it might be beneficial to note that IQVIA’s earnings call indicated double-digit request-for-proposal growth from emerging biopharmas. This sentiment appears to be consistent across the industry. We are continuing to monitor this trend.

In this article, researchers discuss additional machine learning applications in their long COVID-19 research, challenges and what they hope to accomplish over time.

President Biden plans to attend the White House Correspondents’ Association dinner this year. This is the first time a sitting president has attended since 2016. This article explores the reality that COVID-19 is still a challenge in the U.S. and the important risks to consider, even for a president.

The FDA recently expanded the approval of the COVID-19 treatment Veklury (remdesivir) to include pediatric patients 28 days of age and older, weighing approximately 7 pounds or more, who test positive for the virus. Patients would have to be already hospitalized or at high risk for hospitalization. Veklury is the first approved COVID-19 treatment for children less than 12 years of age.

Source link